Denali Therapeutics Inc. | Small-cap | Healthcare
$13.44
-2.82%
| Denali Therapeutics Stock Comparison:
Denali Therapeutics vs VertexDenali Therapeutics vs RegeneronDenali Therapeutics vs Harmony BiosciencesDenali Therapeutics vs Amicus TherapeuticsDenali Therapeutics vs Ocular TherapeutixDenali Therapeutics vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 0
Operating Income -145.6M
Net Income -133.0M
EPS (Diluted) $-0.78

Balance Sheet Metrics

Total Assets 1.3B
Total Liabilities 148.7M
Shareholders Equity 1.1B
Debt to Equity 0.13

Cash Flow Metrics

Operating Cash Flow -92.5M
Free Cash Flow -136.5M

Revenue & Profitability Trend

Denali Therapeutics Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i0330.5M108.5M48.7M335.7M
Cost of Goods Sold i-----
Gross Profit i-----
Gross Margin % i0.0%0.0%0.0%0.0%0.0%
Operating Expenses
Research & Development i396.4M423.9M358.7M265.4M212.6M
Selling, General & Administrative i105.4M103.4M90.5M79.1M60.3M
Other Operating Expenses i-----
Total Operating Expenses i501.9M527.2M449.2M344.4M272.9M
Operating Income i-501.9M-196.7M-340.7M-295.8M62.7M
Operating Margin % i0.0%-59.5%-314.2%-607.8%18.7%
Non-Operating Items
Interest Income i64.6M51.5M14.8M4.6M9.2M
Interest Expense i-----
Other Non-Operating Income14.5M----
Pre-tax Income i-422.7M-145.2M-326.0M-291.2M72.0M
Income Tax i68.0K30.0K21.0K-575.0K823.0K
Effective Tax Rate % i0.0%0.0%0.0%0.0%1.1%
Net Income i-422.8M-145.2M-326.0M-290.6M71.1M
Net Margin % i0.0%-43.9%-300.6%-597.2%21.2%
Key Metrics
EBITDA i-507.4M-180.0M-330.4M-287.2M71.2M
EPS (Basic) i$-2.57$-1.06$-2.60$-2.39$0.65
EPS (Diluted) i$-2.57$-1.06$-2.60$-2.39$0.63
Basic Shares Outstanding i164473772137370897125530703121524795108974137
Diluted Shares Outstanding i164473772137370897125530703121524795108974137

Income Statement Trend

Denali Therapeutics Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i175.0M127.1M218.0M293.5M507.1M
Short-term Investments i657.4M907.4M1.1B571.9M962.6M
Accounts Receivable i2.2M3.4M9.3M--
Inventory i-----
Other Current Assets--36.1M30.6M20.3M
Total Current Assets i864.4M1.1B1.4B897.2M1.5B
Non-Current Assets
Property, Plant & Equipment i126.9M72.8M64.9M60.9M56.8M
Goodwill i-----
Intangible Assets i-----
Long-term Investments-----
Other Non-Current Assets24.7M18.1M13.4M11.9M2.5M
Total Non-Current Assets i509.7M89.8M87.9M506.9M108.6M
Total Assets i1.4B1.2B1.5B1.4B1.6B
Liabilities
Current Liabilities
Accounts Payable i11.1M9.5M2.8M4.8M1.1M
Short-term Debt i12.0M7.3M7.3M5.5M4.7M
Current Portion of Long-term Debt-----
Other Current Liabilities-----
Total Current Liabilities i102.2M78.0M363.9M378.2M71.7M
Non-Current Liabilities
Long-term Debt i36.7M45.0M53.0M58.6M64.2M
Deferred Tax Liabilities i-----
Other Non-Current Liabilities5.6M-379.0K379.0K701.0K
Total Non-Current Liabilities i42.3M45.0M53.9M63.6M382.0M
Total Liabilities i144.5M123.0M417.8M441.9M453.7M
Equity
Common Stock i1.8M1.7M1.7M1.5M1.5M
Retained Earnings i-1.5B-1.1B-971.0M-645.0M-354.4M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i1.2B1.0B1.0B962.3M1.2B
Key Metrics
Total Debt i48.7M52.2M60.4M64.0M68.9M
Working Capital i762.2M986.2M1.0B519.0M1.4B

Balance Sheet Composition

Denali Therapeutics Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-422.8M-145.2M-326.0M-290.6M71.1M
Depreciation & Amortization i9.0M16.7M10.4M8.6M8.5M
Stock-Based Compensation i102.9M108.1M99.8M85.2M50.4M
Working Capital Changes i2.0M-288.5M-32.2M-12.3M276.9M
Operating Cash Flow i-312.9M-312.6M-251.2M-212.0M404.6M
Investing Activities
Capital Expenditures i-15.9M-12.9M-17.8M-8.5M-3.1M
Acquisitions i-----
Investment Purchases i-1.2B-1.8B-1.1B-1.4B-1.3B
Investment Sales i1.2B2.1B991.5M1.4B665.4M
Investing Cash Flow i-88.8M249.3M-141.4M-21.6M-623.2M
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i-----
Debt Repayment i-32.3M----
Financing Cash Flow i466.9M0296.2M0614.1M
Free Cash Flow i-363.6M-370.9M-262.5M-219.9M413.1M
Net Change in Cash i65.2M-63.3M-96.4M-233.6M395.4M

Cash Flow Trend

Denali Therapeutics Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -5.23
Forward P/E -4.89
Price to Book 1.74
PEG Ratio -4.89

Profitability Ratios

Profit Margin 0.00%
Operating Margin 0.00%
Return on Equity -35.21%
Return on Assets -22.58%

Financial Health

Current Ratio 9.56
Debt to Equity 4.59
Beta 1.33

Per Share Data

EPS (TTM) $-2.67
Book Value per Share $7.73
Revenue per Share $0.00

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
dnli2.0B-5.231.74-35.21%0.00%4.59
Vertex 118.7B32.827.20-5.64%-8.91%10.00
Regeneron 58.9B14.082.0415.96%31.94%9.20
Harmony Biosciences 2.0B13.132.7424.71%20.50%24.63
Amicus Therapeutics 1.9B-35.119.53-22.62%-6.67%216.99
Ocular Therapeutix 1.9B-7.14-57.19%91.17%28.66

Financial data is updated regularly. All figures are in the company's reporting currency.